NCT05922501 - Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions

Relapsed CancerRefractory Multiple MyelomaMultiple Myeloma

Interventions

DRUG

Isatuximab

An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.

DRUG

Belantamab mafodotin

An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.

DRUG

Pomalidomide

An immunomodulatory agent, capsule taken orally.

DRUG

Dexamethasone

A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.

Trial Locations (2)

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston